Douglas S. Rohlen serves as Independent Director of the Company. He is the founder and Chief Executive Officer of Ajax Health, a holding company that funds and operates innovative healthcare companies, where he has served since May 2017. Prior to that, from December 2013 to May 2019, he co-founded and served as the chairman and Chief Executive Officer of EPIX Therapeutics, which was acquired by Medtronic in 2019. He also co-founded and served as Chief Executive Officer of Spirox, which was acquired by Entellus in 2017; and CV Ingenuity, which was acquired by Covidien in 2013. Previously Mr. Rohlen was the president of Foxhollow Technologies.
Douglas Rohlen is 52, he's been the Independent Director of Eidos Therapeutics Inc since 2020. There are 4 older and 3 younger executives at Eidos Therapeutics Inc. The oldest executive at Eidos Therapeutics Inc is Uma Sinha, 63, who is the Chief Scientific Officer, Director.
Douglas's mailing address filed with the SEC is C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2000, SAN FRANCISCO, CA, 94104.
Over the last 6 years, insiders at Eidos Therapeutics Inc have traded over $18,169,563 worth of Eidos Therapeutics Inc stock and bought 30,345,136 units worth $349,599,962 . The most active insiders traders include Capital Management, L.P.Ra ..., Pharma, Inc. Bridge Bio a Rajeev M. Shah. On average, Eidos Therapeutics Inc executives and independent directors trade stock every 13 days with the average trade being worth of $52,576,942. The most recent stock trade was executed by Pharma, Inc. Bridge Bio on 26 January 2021, trading 14,428,836 units of EIDX stock currently worth $1,763,348,048.
Eidos Therapeutics Inc executives and other stock owners filed with the SEC include: